Core Viewpoint - The announcement details the regulatory measures and penalties faced by Borui Biopharmaceuticals (Suzhou) Co., Ltd. over the past five years, emphasizing the company's commitment to compliance and governance improvements. Recent Regulatory Penalties - The company and its directors, supervisors, and senior management have not faced any penalties from regulatory authorities in the last five years [1] Recent Regulatory Measures and Rectification - On February 13, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the company's announcement on antiviral drug research progress, requiring clarification on the commercialization timeline and potential patent infringements related to the production of remdesivir [2] - The company responded that the remdesivir project is still in the preclinical research stage and that its production is limited to research purposes, thus not infringing on Gilead's patents [2][3] - On March 1, 2020, the Shanghai Stock Exchange issued a decision to place the company under regulatory scrutiny due to unclear information disclosure regarding the distinction between experimental production and commercial production [4] - The former board secretary was criticized for further confusing the terms during a media interview, leading to regulatory actions against him [5] - On March 11, 2020, the Jiangsu Securities Regulatory Bureau issued a warning letter, confirming that the company's disclosure of "batch production" was misleading and did not accurately reflect the drug development progress [7] - On June 30, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the establishment of an investment fund, requiring the company to enhance internal control mechanisms and ensure compliance in external investments [8] - On October 17, 2023, a warning letter was issued to an individual for misleading statements regarding a product still in clinical trials, emphasizing the need for accurate information disclosure [9] - On June 20, 2025, a warning letter was issued due to the company's failure to timely redeem idle fundraising cash management products, violating disclosure obligations [10][12] - The company has committed to improving compliance and internal management practices in response to these regulatory measures [11][14]

Core Viewpoint - The announcement discusses the impact of the company's planned issuance of A-shares to specific investors on immediate returns and outlines measures to mitigate potential dilution effects on shareholder returns [2][5]. Financial Impact Analysis - The company conducted a thorough analysis of the impact of the A-share issuance on key financial metrics, assuming no significant changes in the company's situation [2]. - As of December 31, 2024, the total share capital before the issuance is 42,246.66 million shares, which will increase to 44,482.80 million shares post-issuance [3]. - Three scenarios were analyzed for the projected net profit attributable to shareholders for 2025: a 10% increase, no change, and a 10% decrease compared to 2024 [4]. Scenario 1: No Growth - Net profit remains at 18,050.75 million yuan, resulting in diluted earnings per share of 0.44 yuan [4]. Scenario 2: 10% Growth - Net profit increases to 19,855.82 million yuan, leading to diluted earnings per share of 0.49 yuan [4]. Scenario 3: 10% Decline - Net profit decreases to 16,245.67 million yuan, resulting in diluted earnings per share of 0.40 yuan [4]. Necessity and Reasonableness of the Issuance - The issuance plan has undergone careful consideration and analysis, focusing on the feasibility of using the raised funds to support the company's core business and strategic development [5]. Measures to Mitigate Dilution Effects - The company plans to enhance its competitiveness by adhering to a "research-driven" and "internationalization" strategy, focusing on improving product quality and accelerating new product commercialization [6]. - Operational efficiency will be improved to reduce costs across various management areas, including production and financial management [6]. - A strict fundraising management system will be implemented to ensure proper use and oversight of the raised funds [7][8]. - The company aims to maintain a stable profit distribution system to strengthen investor return mechanisms [8]. Commitments from Relevant Parties - The controlling shareholders and management have made commitments to uphold shareholder rights and ensure compliance with relevant regulations, promising to bear legal responsibilities for any violations [10][11].

证券代码：688166 证券简称：博瑞医药 公告编号：2025-050 博瑞生物医药（苏州）股份有限公司 关于与特定对象签署附条件生效的股份认购协议的 补充协议暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）拟向特定对 象袁建栋先生发行 A 股股票（以下简称"本次发行"），发行股票数量不超过 最终认购本次发行的股数为实际认购金额除以认购价格，对认购股份数量不足 1 股的尾数作舍去处理。 ? 袁建栋先生为公司控股股东、实际控制人之一，系公司关联方，根据《上 海证券交易所科创板股票上市规则》的规定，本次发行构成关联交易，但不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。 ? 本次发行尚需经上海证券交易所审核和报经中国证监会履行发行注册程 序，能否获得上述审批和注册以及上述审批和注册的时间均存在不确定性。 一、关联交易概述 （一）本次交易基本情况 《关于公司 2024 年度向特定对象发行 A 股股票方案的议案》 《关于公司 20 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-052 博瑞生物医药（苏州）股份公司 何方式减持博瑞医药股份，也不存在减持博瑞医药股份的计划； 《上市公司收购管理办法》 等法律法规、交易所的相关规定进行减持并履行权益变动涉及的信息披露义务； 博瑞医药所有； 个月内不转让；因博瑞医药分配股票股利、资本公积转增资本等情形所衍生取得 的股票亦应遵守上述股份锁定安排。法律、法规、规范性文件对限售期另有规定 的，依其规定。如果中国证监会、上海证券交易所对于上述限售期安排有不同意 见，本人承诺按照中国证监会、上海证券交易所的意见对上述限售期安排进行修 订并予执行。限售期满后，本人减持所认购的本次发行的股票将按中国证监会及 上海证券交易所的有关规定执行； 关于袁建栋就公司 2024 年度向特定对象发行股票相关 事宜出具承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 博瑞生物医药（苏州）股份公司（以下简称"公司"）于 2024 年 5 月 6 日召 开第三届董事会第二十六次会议、第三届监事会第二十四次会议以及 ...

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 与特定对象签署附条件生效的股份认购协议的补充协议 暨涉及关联交易的核查意见 民生证券股份有限公司（以下简称"民生证券"）作为博瑞生物医药（苏州） 股份有限公司（以下简称"博瑞医药"或"公司"）持续督导的保荐机构，履行 持续督导职责，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创 板股票上市规则》等规范性法律文件的要求，对博瑞医药对与特定对象签署《关 于 <博瑞生物医药 a="A" ensp="ensp" 股份有限公司向特定对象发行="股份有限公司向特定对象发行" 股 股票之附条件生效="股股票之附条件生效" 苏州="苏州"> 的股份认购协议>的补充协议》（以下简称"补充协议"）暨涉及关联交易事宜 进行了审慎核查，核查情况及意见如下： 一、关联交易概述 公司于 2024 年 5 月 6 日召开的第三届董事会第二十六次会议以及 2024 年 5 月 20 日召开的 2023 年年度股东大会，审议通过了《关于公司 2024 年度向特定 对象发行 A 股股票方案的议案》《关于公司 2024 年度向特定对象发行 A 股股票 预案的议案》《关于公司与特 ...

《博瑞生物医药（苏州）股份有限公司 2024 年度向特定对象发行 A 股股票 预案（二次修订稿）》《博瑞生物医药（苏州）股份有限公司 2024 年度向特定对 象发行 A 股股票方案的论证分析报告（二次修订稿） 证券代码：688166 证券简称：博瑞医药 公告编号：2025-047 博瑞生物医药（苏州）股份有限公司 关于 2024 年度向特定对象发行 A 股股票预案（二次修 订稿）披露的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）于 2025 年 7 月 了关于修订公司 2024 年度向特定对象发行 A 股股票预案的议案等相关议案。 博瑞生物医药（苏州）股份有限公司董事会 》等相关文件于同日在上海 证券交易所网站（www.sse.com.cn）披露，敬请广大投资者注意查阅。 本次公司 2024 年度向特定对象发行 A 股股票预案的披露事项不代表审核、 注册部门对于本次发行相关事项的实质性判断、确认或批准，向特定对象发行股 票预案所述本次发行相关事项的生效和完 ...

Core Viewpoint - The establishment of the Sci-Tech Innovation Board (STAR Market) has provided a favorable development platform for China's technology innovation enterprises, supported by policies and a more inclusive financing environment [1][3]. Group 1: Support for Sci-Tech Enterprises - Sci-Tech enterprises face challenges such as long R&D cycles, high funding requirements, and significant failure risks, necessitating support from policies, funding, and technology [3]. - The STAR Market has evolved to provide precise support for listed Sci-Tech enterprises, showcasing positive development trends [3]. - Companies like Boryung Pharmaceutical have transitioned from complex generic drug production to innovative drug R&D, benefiting from the financial support provided by the STAR Market [4]. Group 2: Capital Empowerment and Innovation - Boryung Pharmaceutical has invested a total of 1.2 billion yuan in R&D over six years, with key innovative drugs entering critical clinical phases [4]. - Haoyuan Pharmaceutical has rapidly developed its drug R&D center and production base after listing on the STAR Market, enhancing its service capabilities for the innovative drug industry [4]. Group 3: AI Technology and Innovation - The rapid development of AI technology, particularly in vertical applications, is empowering innovation across various industries [5]. - AI models are adept at solving complex nonlinear problems, helping to overcome innovation bottlenecks in fields like biomedicine and materials science [5]. - The China Securities Index Company has been enhancing the STAR Market index system to guide social capital towards key supported areas, promoting high-quality development of Sci-Tech companies [5][6]. Group 4: Future Developments and Market Dynamics - The STAR Market is set to undergo institutional upgrades with the introduction of the "1+6" policy, improving financing channels for Sci-Tech enterprises [8]. - The deepening reforms aim to enhance inclusivity for hard-tech companies, particularly in biomedicine and high-end equipment sectors [8]. - The integration of AI technology is expected to reduce investment risks and enhance innovation capabilities in the biopharmaceutical sector, leading to higher returns on investment [9]. Group 5: Global Recognition and Competitive Advantage - China's overall innovation capability is gaining global recognition, with a significant increase in domestic biopharmaceutical intellectual property cases being exported [9]. - As China's Sci-Tech strength continues to grow, the capital market's risk appetite for innovative drug companies is expected to shift positively, further enhancing competitiveness in the global market [9].

Group 1 - The establishment of the Sci-Tech Innovation Board (STAR Market) has provided a favorable development platform for Chinese technology innovation enterprises, supported by innovative market mechanisms and inclusive financing environments [1] - The introduction of policies such as "STAR Market Eight Articles" and "1+6" aims to alleviate the challenges faced by high-quality technology enterprises, injecting momentum into China's economic transformation and the development of new productive forces [1] - The STAR Market has become a "testing ground" for capital market reforms, effectively supporting strategic emerging industries and empowering technological innovation [3][4] Group 2 - Small and medium-sized technology enterprises face significant challenges, including long R&D cycles, high capital investment, and substantial failure risks, necessitating support from policies, funding, and technology [3] - Companies like Borui Pharmaceutical have successfully transitioned from complex generic drug production to innovative drug development, with cumulative R&D investment reaching 1.2 billion yuan (approximately 0.17 billion USD) over six years [4] - The rapid development of AI technology is enhancing innovation capabilities across various industries, with AI models helping to solve complex problems and break through innovation bottlenecks [4][6] Group 3 - The STAR Market's recent reforms, including the establishment of a growth tier and the reintroduction of listing standards for unprofitable companies, are expected to improve inclusivity for hard-tech enterprises and broaden financing channels [6] - The integration of AI technology into the drug development process is significantly shortening R&D cycles and increasing success rates, leading to higher returns on investment in innovative drugs [6][7] - The overall innovation capability of Chinese enterprises is gaining global recognition, with an increase in domestic biopharmaceutical intellectual property being exported [7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688166 证券简称：博瑞医药 公告编号：2025-047 博瑞生物医药（苏州）股份有限公司 关于 2024 年度向特定对象发行 A 股股票预案（二次修 订稿）披露的提示性公告 特此公告。 博瑞生物医药（苏州）股份有限公司董事会 2025 年 7 月 19 日 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）于 2025 年 7 月 18 日召开第四届董事会第九次会议、第四届监事会第八次会议，会议审议通过 了关于修订公司 2024 年度向特定对象发行 A 股股票预案的议案等相关议案。 《博瑞生物医药（苏州）股份有限公司 2024 年度向特定对象发行 A 股股票 预案（二次修订稿）》《博瑞生物医药（苏州）股份有限公司 2024 年度向特定对 象发行 A 股股票方案的论证分析报告（二次修订稿）》等相关文件于同日在上海 证券交易所网站（www.sse.com.cn）披露，敬请广大投资者注意查阅。 本次公司 2024 年度向特定对象发行 A 股股票预案的披露事项不代表 ...

博瑞生物医药（苏州）股份有限公司 BrightGene Bio-Medical Technology Co., Ltd. （苏州工业园区星湖街 218 号纳米科技园 C25 栋） 2024 年度向特定对象发行 A 股股票预案 （二次修订稿） 证券简称：博瑞医药 证券代码：688166 二〇二五年七月 1 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏。 2、本预案按照《上市公司证券发行注册管理办法》等法规及规范性文件的 要求编制。 3、本次向特定对象发行股票完成后，公司经营与收益的变化由公司自行负 责；因本次向特定对象发行股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行股票的说明，任何与之相反 的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行股票相关事 项的实质性判断、确认、批准或核准，本预案所述本次向特定对象发行股票相关 事项的生效和完成尚待上海证券交易所审核通过并经中国证监会作出同意注册 决定。 ...